Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06752577

Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)

The purpose of this protocol is to treat an intermediate-sized population with chronic kidney disease (CKD) including kidney transplant recipients. The protocol uses allogeneic bone marrow-derived mesenchymal stem cells (MSCs). MSC infusion may be delivered 1) intravenous or 2) intravenous plus intra-arterial to both kidneys. Individuals will have subsequent follow up for safety evaluations. Repeat dosing is allowed.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mayo Clinic

Jacksonville, Florida, 32224, United States

Location status: Recruiting

Location contact

Donna K Lawson

CONTACT

[email protected]

507-255-7975

LaTonya J Hickson, MD

PRINCIPAL_INVESTIGATOR

Regenerative Nephrology Program

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >18 years
  • Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2
  • Hemoglobin A1c ≤9%, if diabetes mellitus present
  • If kidney transplant recipient, must have eGFR<60 mL/min/1.73m2 and evidence of progressive kidney function loss over ≥6 months
  • Ability to give informed consent

Exclusion criteria

  • Anemia (hemoglobin <8.5 g/dL)
  • Body weight >150 kg or BMI >50
  • Uncontrolled hypertension: sustained systolic blood pressure (SBP) >160 mmHg or diastolic blood pressure (DBP) ≥100 mmHg despite maximal doses of at least 2 different classes of anti-hypertensive medications
  • Chronic hypotension history: sustained SBP <85 mmHg
  • Kidney failure requiring ongoing kidney replacement therapy including hemodialysis or peritoneal dialysis
  • Active, high-dose immunosuppression therapy (e.g. chronic prednisone ≥20 mg daily)
  • Solid organ transplantation history; excluding kidney transplant
  • Active treatment for acute cellular rejection, in kidney transplant recipients
  • Recent cardiovascular event (hospitalization for myocardial infarction, stroke, congestive heart failure (NYHA class ≥III or ejection fraction ≤30%) within 3 months or uncontrolled cardiac arrhythmias (e.g. ventricular arrhythmia, supraventricular tachycardia and bradyarrhythmia)
  • History of liver cirrhosis
  • Chronic obstructive pulmonary disease or asthma requiring daily medication
  • History of recurring blood clotting disorder (thromboembolism: pulmonary embolism, deep venous thrombosis) requiring chronic anticoagulation therapy
  • Pregnancy
  • Unwilling to use contraception for at least 2 months after MSC infusion if sexually active and able to become pregnant or father a child.
  • Active malignancy
  • Active infection (e.g. systemic or specific organ involvement such as pneumonia or osteomyelitis; in kidney transplant recipients, active BK nephropathy)
  • Recent COVID-19 infection, within the last 1 month
  • History of hepatitis B or C (without cure), or HIV infection
  • History of allergic reaction to cellular products (i.e. blood transfusions, platelets)
  • Active tobacco use
  • Illicit drug use and excessive alcohol use
  • Presence of psychosocial issues (e.g., uncontrolled mental illness, unpredictable childcare or eldercare responsibilities, irregular/ inflexible work schedule) that may interfere with the ability to complete all study procedures
  • Anticipating prolonged travel or other physical restrictions that would prohibit return for scheduled study visits.
  • Inability to give informed consent

Treatment and study plan

Allogeneic, vertebral bone marrow-derived mesenchymal stem cells (MSC)

Drug
  • intravenous infusion or 2) combined intravenous plus intra-arterial (to kidney) infusion of cells. Total dose: 200x10^6 MSC (administered over 15 minutes to 2 hours). Repeat dosing allowed at 6 month intervals.

Primary outcomes

  1. Adverse events and/or serious adverse events

    Time frame: 6 months after each MSC infusion

    Number of adverse events and/or serious adverse events associated with mesenchymal stem cell (MSC) intervention

Study contacts

Contact information is provided by the study sponsor or research team.

Donna K Lawson

CONTACT

[email protected]

507-255-7975

Mayo Clinic Regenerative Nephrology Program

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Collaborators

  • Ossium Health, Inc.

Registry information

Important dates

Study start
2024
Primary completion
2030
Study completion
2031
First posted
Dec 30, 2024
Registry last updated
Jan 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.